Insights

Phoenix Pharmacy Claims

Earnest Analytics
  • Healthcare
  • Pharmacy

Mounjaro GLP1 leader in 2024
  • Healthcare
  • Pharmacy

Blueprint poised to elevate Ayvakit to blockbuster status with rapid growth in ISM 
  • Healthcare
  • Pharmacy

Madrigal cultivates Rezdiffra’s foothold in MASH as GLP-1 competitors seek approval
  • Healthcare
  • Pharmacy

Winrevair: Potential Blockbuster in PAH
  • Healthcare
  • Pharmacy

Significant number of ex-Mounjaro patients switch to Ozempic 
  • Healthcare
  • Pharmacy

Barriers to GLP1 access drive higher telehealth use by patients living with obesity 
arrow-downarrow-leftarrow-rightcaret-down-menucaret-downcarrot-rightcheckclosefacebook-squarefilterhamburgerinstagram-squarelinkedin-squaremobile-parent-indicatorpauseplayprintertwitter-square